By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT New CEO On February 13, 2025, Sadot Group (NASDAQ:SDOT) announced the appointment of Catia Jorge as new Chief Executive Officer. Ms. Jorge has nearly 30 years of experience in agricultural markets, commodity trading, and operational leadership. Most recently, she served as Brazil Country Head … Read more
By John Vandermosten, CFA NASDAQ:MDAI READ THE FULL MDAI RESEARCH REPORT Since reporting third quarter results in November, Spectral AI, Inc. (NASDAQ:MDAI) has continued to advance its burn program in burn center populations, pediatric burn in emergency departments and with the SnapShot M portable device. Most importantly, Spectral has finished enrollment and evaluation of all … Read more
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for plozasiran for the treatment of familial chylomycronemia syndrome (FCS), with a Prescription Drug User Fee Act … Read more
By Lisa Thompson NASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT Tower (NASDAQ:TSEM) continued year-over-year revenue growth in Q4 2024 and expects that to continue sequentially and year-over-year throughout 2025. The growth will be back-half weighted as capacity comes online in Italy, Texas, and Japan. For the 2024 year, revenues and earnings were basically flat with … Read more
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin … Read more
